Nephro-Urology Monthly

Published by: Kowsar

Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease

Yoshiyuki Morishita 1 , * and Eiji Kusano 1
Authors Information
1 Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan
Article information
  • Nephro-Urology Monthly: December 01, 2012, 5 (1); 668-672
  • Published Online: December 15, 2012
  • Article Type: Review Article
  • Received: December 1, 2011
  • Revised: December 12, 2011
  • Accepted: December 18, 2011
  • DOI: 10.5812/numonthly.3679

To Cite: Morishita Y, Kusano E. Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease, Nephro-Urol Mon. 2012 ; 5(1):668-672. doi: 10.5812/numonthly.3679.

Abstract
Copyright © 2012, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. RAAS in CKD
3. The Effects of Aliskiren on CKD
4. Adverse Effects of Aliskiren on CKD
5. Conclusion
Acknowledgements
Footnotes
References
  • 1. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem. 1974; 20(10): 1255-70[PubMed]
  • 2. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002; 39(1)-8[DOI][PubMed]
  • 3. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006; 17(11): 2985-91[DOI][PubMed]
  • 4. Mann JF, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl. 2003; 84-6[DOI][PubMed]
  • 5. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003; 115(4): 291-7[DOI][PubMed]
  • 6. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation. 2002; 105(11): 1336-41[DOI][PubMed]
  • 7. Blankestijn PJ, Ligtenberg G. Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. Semin Dial. 2004; 17(4): 265-9[DOI][PubMed]
  • 8. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease. Heart. 2004; 90(8): 961-6[DOI][PubMed]
  • 9. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009; 53(5): 860-6[DOI][PubMed]
  • 10. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009; 373(9668): 1009-15[DOI][PubMed]
  • 11. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001; 135(2): 73-78[PubMed]
  • 12. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005; 16(10): 3038-45[DOI][PubMed]
  • 13. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006; 354(2): 131-40[DOI][PubMed]
  • 14. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366(9502): 2026-33[DOI][PubMed]
  • 15. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23): 2433-46[DOI][PubMed]
  • 16. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008; 73(12): 1419-25[DOI][PubMed]
  • 17. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011; 26(9): 2930-4[DOI][PubMed]
  • 18. Moriyam T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, et al. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2012; 44(3): 841-845[DOI][PubMed]
  • 19. Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010; 33(1): 62-6[DOI][PubMed]
  • 20. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi SI. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst. 2012; 13(1): 122-127[DOI][PubMed]
  • 21. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011; 34(3): 308-13[DOI][PubMed]
  • 22. Davalos M, Frega NS, Saker B, Leaf A. Effect of exogenous and endogenous angiotensin II in the isolated perfused rat kidney. Am J Physio. 1978; 235(6)-10[PubMed]
  • 23. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl. 1987; 20-11[PubMed]
  • 24. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001; 38(3 Pt 2): 635-8[DOI][PubMed]
  • 25. Mimran A, Shaldon S, Barjon P, Mion C. The effect of an angiotensin antagonist (saralasin) on arterial pressure and plasma aldosterone in hemodialysis-resistant hypertensive patients. Clin Nephrol. 1978; 9(2): 63-7[PubMed]
  • 26. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990; 137(1): 7-12[PubMed]
  • 27. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991; 68(2): 450-6[DOI][PubMed]
  • 28. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens. 2000; 18(9): 1207-13[DOI][PubMed]
  • 29. Landomesser U, Drexler H. oxidative stress, the renin-angiotensin system, and atherosclerosis. Europ Heart J. 2003; 5[DOI]
  • 30. Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail. 2006; 28(5): 427-33[DOI][PubMed]
  • 31. Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet. 2007; 46(8): 661-75[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments